Today: 16 May 2026
Intel Corporation’s 18A Bet Faces First Market Test as Business PCs Arrive Tuesday
30 March 2026
2 mins read

Intel Corporation’s 18A Bet Faces First Market Test as Business PCs Arrive Tuesday

NEW YORK, March 30, 2026, 09:12 EDT

Intel Corporation’s initial commercial PCs featuring its 18A process are slated to land with customers Tuesday, Dell among the earliest to deliver systems. The chipmaker said PCs using its Core Ultra Series 3 and vPro platform—covering management and security—will hit the market starting March 31. Dell has its Pro 14 Premium, Pro 5 Micro, and Pro Precision 7 lined up for release that same day.

The 18A rollout is key. Intel’s latest chipmaking technology underpins Chief Executive Lip-Bu Tan’s push to reclaim manufacturing dominance and shore up its foundry business. The timing is notable: companies are still upgrading to Windows 11, but higher memory prices could soon drive up PC costs and dampen appetite.

Intel’s commercial lineup includes over 125 models—laptops, desktops, workstations all in. David Feng, VP in the client computing group, described the offering as “the most expansive” portfolio the company’s brought out to date. The vPro platform targets IT departments looking for scalable device management and security features. Newsroom

Intel gets an early foothold in the corporate space with Dell’s rollout, but it’s no monopoly. Dell will sell its new commercial laptops and workstations with a choice between Intel’s Core Ultra Series 3 and AMD’s Ryzen AI 400 chips. Analyst Pat Moorhead flagged that enterprises are deep into a “major PC refresh cycle,” balancing security, manageability, and flexible workloads, all while navigating choppy supply chains. Dell

Tuesday’s rollout goes beyond a routine product launch. Earlier this month, Intel CFO David Zinsner said Tan now views 18A as “a good node” for external clients too—a significant pivot, considering Intel had previously aimed to keep the process for its own chips. Reuters

Intel heads into the test with the margin for mistakes razor-thin. Back in January, the chipmaker acknowledged it couldn’t keep up with demand for server CPUs that complement Nvidia’s AI chips, and its first-quarter revenue outlook missed Wall Street’s mark. Tan voiced his frustration to analysts over Intel’s inability to completely meet customer needs right away.

Competitive pressure isn’t letting up. Arm’s AGI CPU announcement last week sparked a 20% rally in its stock, with Intel and AMD both climbing over 5%—evidence investors see a bigger AI opportunity for classic CPUs. In the PC space, Intel’s own launch partners aren’t shutting out AMD, which is still getting its share of the action.

PC makers are staring down a tougher market. Gartner reports global PC shipments rose 9.1% in 2025, largely on the back of Windows 11 refreshes, but it’s bracing for a 10.4% drop in 2026 as DRAM and SSD costs head higher. According to Ranjit Atwal, senior director analyst at Gartner, the first half of 2026 is shaping up as a “critical window” for vendors to shore up margins before component price hikes take hold. Gartner

Intel faces a risk: AI PCs—machines built to process some AI tasks locally—might not deliver returns as quickly as chipmakers once thought. Gartner is warning that AI PC uptake could slow through 2027. Intel itself admits margins are tied closely to yields, or the number of good chips produced from each silicon wafer. Meanwhile, Dell is already selling AMD-powered options in the same product lines.

Shares of Intel slipped roughly 2.2% to $43.13 just ahead of Monday’s open.

Stock Market Today

  • W. R. Berkley (WRB) Shows 45.9% Undervaluation Despite Recent Price Stability
    May 15, 2026, 7:55 PM EDT. W. R. Berkley (WRB) stock has shown limited movement recently with a 1.2% gain over 7 days and a 4.2% decline year-to-date. Analysts use valuation methods like Excess Returns, which estimates intrinsic value by calculating profits above shareholder required returns. With an intrinsic value estimate of $122.79 against a current price near $66.45, the stock appears 45.9% undervalued. The insurer's steady underwriting profile and capital discipline contrast with sector concerns on insurance pricing and interest rate sensitivity. WRB currently scores 2 out of 6 on valuation metrics, highlighting potential but raising caution.

Latest articles

Accuray inks 10-year cancer tech agreement, shares in focus

Accuray inks 10-year cancer tech agreement, shares in focus

16 May 2026
Accuray and the University of Wisconsin School of Medicine and Public Health signed a 10-year research agreement focused on Accuray’s Stellar adaptive radiotherapy platform. The announcement came after market close, with Accuray shares ending down 5.2% at $0.27. The deal follows Accuray’s recent withdrawal of fiscal 2026 guidance and ongoing financial pressures.
Origin Materials Gains as Filing Signals $3.54 Liquidation Payout Possible

Origin Materials Gains as Filing Signals $3.54 Liquidation Payout Possible

16 May 2026
Origin Materials asked shareholders to approve a plan to liquidate and dissolve the company, estimating an initial payout of $0.61 to $3.54 per share depending on asset sales and claims. Shares rose 15% to $1.43 after the filing. The company reported a 91% drop in first-quarter revenue and warned it may not survive without the wind-down. Origin cut 59% of its workforce and CEO John Bissell stepped down May 1.
NextNRG Q1 Revenue Gains, but Company Holds Cash Warning

NextNRG Q1 Revenue Gains, but Company Holds Cash Warning

16 May 2026
NextNRG reported first-quarter revenue of $21.1 million, up 29% from a year earlier, but its net loss widened to $10.8 million. Cash fell to $208,048 at quarter-end, and management warned it needs immediate capital to continue operations. Shares closed at $0.2804 on Nasdaq, down nearly 6%. Total liabilities reached $34.3 million, with a stockholders’ deficit of $22 million.
HCW Biologics jumps 262% after Trimmune deal, Q1 profit, Nasdaq risk update

HCW Biologics jumps 262% after Trimmune deal, Q1 profit, Nasdaq risk update

16 May 2026
HCW Biologics shares jumped 262% to $1.22 Friday after the company posted a $3.47 million first-quarter profit, driven by a $6.5 million licensing deal with Beijing Trimmune Biotech. The company faces a possible Nasdaq delisting and will ask shareholders to approve a reverse stock split on June 15. HCW plans to report early Phase 1 data for its alopecia drug in the first half of 2026.
CrowdStrike Stock Rises After Wolfe Upgrade as Anthropic AI Fears Turn Into Cybersecurity Spending Bet
Previous Story

CrowdStrike Stock Rises After Wolfe Upgrade as Anthropic AI Fears Turn Into Cybersecurity Spending Bet

AST SpaceMobile Sets April 10 BlueBird 7 Target as Rocket Lab Notches ESA Launch After SpaceX IPO Buzz
Next Story

AST SpaceMobile Sets April 10 BlueBird 7 Target as Rocket Lab Notches ESA Launch After SpaceX IPO Buzz

Go toTop